Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.
The protein transduction domain from human immunodeficiency virus (HIV) Tat allows proteins to penetrate the cell membrane. Enhanced cellular uptake of therapeutic proteins could benefit a number of disorders. This is especially true for lysosomal storage disorders (LSDs) where enzyme replacement therapy (ERT) and gene therapy have been developed. We developed a novel recombinant lentiviral vector (LV) that engineers expression of alpha-galactosidase A (alpha-gal A)-Tat fusion protein for correction of Fabry disease, the second-most prevalent LSD with manifestations in the brain, kidney and heart. In vitro experiments confirmed mannose-6-phosphate independent uptake of the fusion factor. Next, concentrated therapeutic LV was injected into neonatal Fabry mice. Analysis of tissues at 26 wks demonstrated similar alpha-gal A enzyme activities but enhanced globotriaosylceramide (Gb3) reduction in hearts and kidneys compared with the alpha-gal A LV control. This strategy might advance not only gene therapy for Fabry disease and other LSDs, but also ERT, especially for cardiac Fabry disease.
Higuchi
Koji
K
University Health Network (UHN), Toronto, Ontario, Canada.
Yoshimitsu
Makoto
M
Fan
Xin
X
Guo
Xiaoxin
X
Rasaiah
Vanessa I
VI
Yen
Jennifer
J
Tei
Chuwa
C
Takenaka
Toshihiro
T
Medin
Jeffrey A
JA
D000818:Animals; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy / Q000379:methods*; D000795:Fabry Disease / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D015756:Genes, tat; D015316:Genetic Therapy / Q000379:methods*; D006678:HIV / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D007668:Kidney / Q000201:enzymology / Q000378:metabolism; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014161:Transduction, Genetic; D014281:Trihexosylceramides / Q000378:metabolism; D000519:alpha-Galactosidase / Q000097:blood / Q000235:genetics / Q000378:metabolism*
D014281:Trihexosylceramides; C018549:globotriaosylceramide; D000519:alpha-Galactosidase
Mol Ther. 2005 Aug;12(2):345-52
16043103
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7515-20
10840053
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7917-22
8755577
J Biol Chem. 1996 Jul 26;271(30):18188-93
8663410
Circulation. 2002 Mar 26;105(12):1407-11
11914245
J Am Soc Nephrol. 2009 May;20(5):1132-9
19357250
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3428-33
11248095
Ann Intern Med. 2007 Jan 16;146(2):77-86
17179052
Nat Biotechnol. 2001 Jul;19(7):640-4
11433275
N Engl J Med. 1967 May 25;276(21):1163-7
6023233
J Biol Chem. 1997 Jun 20;272(25):16010-7
9188504
Circulation. 2009 Feb 3;119(4):524-9
19153271
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16909-14
15550536
Biochem Biophys Res Commun. 2005 Nov 18;337(2):701-7
16223608
Microbes Infect. 2006 Apr;8(5):1347-57
16697675
Gene Ther. 2007 Feb;14(3):256-65
16929352
N Engl J Med. 1995 Aug 3;333(5):288-93
7596372